E Wiesik-Szewczyk

Summary

Publications

  1. ncbi request reprint [Should we vaccinate patients with systemic lupus]
    Ewa Wiesik-Szewczyk
    Klinika i Poliklinika Układowych Chorób Tkanki Łacznej w Warszawie, Instytut Reumatologii
    Pol Merkur Lekarski 23:395-8. 2007
  2. pmc B-cell targeted therapy in systemic lupus erythematosus: potential of rituximab
    E Wiesik-Szewczyk
    Institute of Rheumatology, Department of Connective Tissue Diseases, Warsaw, Poland
    Biologics 6:347-54. 2012
  3. doi request reprint Anti-influenza vaccination in systemic lupus erythematosus patients: an analysis of specific humoral response and vaccination safety
    Ewa Wiesik-Szewczyk
    Department of Systemic Connective Tissue Diseases, Institute of Rheumatology, Spartanska 1, 02 637, Warsaw, Poland
    Clin Rheumatol 29:605-13. 2010
  4. ncbi request reprint [Contemporaneous clinical picture of systemic sclerosis]
    Ewa Wiesik-Szewczyk
    Instytut Reumatologii w Warszawie, Klinika i Poliklinika Układowych Chorób Tkanki Łacznej
    Pol Merkur Lekarski 28:416-20. 2010
  5. ncbi request reprint [Management of patients with systemic sclerosis]
    Ewa Wiesik-Szewczyk
    Instytut Reumatologii, Klinika i Poliklinika Układowych Chorób Tkanki Łacznej
    Pol Merkur Lekarski 28:421-3. 2010
  6. ncbi request reprint Target therapies in systemic lupus erythematosus: current state of the art
    E Wiesik-Szewczyk
    Institute of Rheumatology, Department of Connective Tissue Diseases, Warsaw, Poland
    Mini Rev Med Chem 10:956-65. 2010
  7. ncbi request reprint [Biological therapies of systemic lupus erythematosus]
    Marzena Olesinska
    Instytut Reumatologii w Warszawie, Klinika Chorób Tkanki Lacznej
    Pol Merkur Lekarski 20:371-3. 2006
  8. ncbi request reprint [Evaluation of systemic lupus erythematosus activity during pregnancy]
    Marzena Olesinska
    Klinika i Poliklinika Układowych Chorób Tkanki Lacznej, Instytut Reumatologii, Warszawa
    Pol Arch Med Wewn 117:312-6. 2007

Detail Information

Publications8

  1. ncbi request reprint [Should we vaccinate patients with systemic lupus]
    Ewa Wiesik-Szewczyk
    Klinika i Poliklinika Układowych Chorób Tkanki Łacznej w Warszawie, Instytut Reumatologii
    Pol Merkur Lekarski 23:395-8. 2007
    ..In this review we would like to present data concerning safety and efficacy of vaccines in patients with SLE to help doctor to decide when vaccination is advisable and when should be avoided...
  2. pmc B-cell targeted therapy in systemic lupus erythematosus: potential of rituximab
    E Wiesik-Szewczyk
    Institute of Rheumatology, Department of Connective Tissue Diseases, Warsaw, Poland
    Biologics 6:347-54. 2012
    ..However data from open source and observational studies contrast with clinical trials results. The global analysis of this data supports the off-label use of rituximab in subsets of SLE that are refractory to standard treatment...
  3. doi request reprint Anti-influenza vaccination in systemic lupus erythematosus patients: an analysis of specific humoral response and vaccination safety
    Ewa Wiesik-Szewczyk
    Department of Systemic Connective Tissue Diseases, Institute of Rheumatology, Spartanska 1, 02 637, Warsaw, Poland
    Clin Rheumatol 29:605-13. 2010
    ..05). The post-vaccination response was weaker in SLE patients compared to healthy subjects. Immunisation did not change underlying disease activity...
  4. ncbi request reprint [Contemporaneous clinical picture of systemic sclerosis]
    Ewa Wiesik-Szewczyk
    Instytut Reumatologii w Warszawie, Klinika i Poliklinika Układowych Chorób Tkanki Łacznej
    Pol Merkur Lekarski 28:416-20. 2010
    ..Factors related to scleroderma renal crisis are presented, to provide clinical evaluation of patients at risk of this complication...
  5. ncbi request reprint [Management of patients with systemic sclerosis]
    Ewa Wiesik-Szewczyk
    Instytut Reumatologii, Klinika i Poliklinika Układowych Chorób Tkanki Łacznej
    Pol Merkur Lekarski 28:421-3. 2010
    ..Despite intensive investigations disease modifying drug therapy is still unknown, but specific organ treatment increase survival and improve health related quality of life...
  6. ncbi request reprint Target therapies in systemic lupus erythematosus: current state of the art
    E Wiesik-Szewczyk
    Institute of Rheumatology, Department of Connective Tissue Diseases, Warsaw, Poland
    Mini Rev Med Chem 10:956-65. 2010
    ..Future studies are likely to focus on specific organ involvement or treatment combinations with other immunosuppressive agents...
  7. ncbi request reprint [Biological therapies of systemic lupus erythematosus]
    Marzena Olesinska
    Instytut Reumatologii w Warszawie, Klinika Chorób Tkanki Lacznej
    Pol Merkur Lekarski 20:371-3. 2006
    ..T cells and B cells activation, antibodies production, cytokines and complement components activation. Pathogenic basis of using these therapies, their safety and efficacy assessment have been presented...
  8. ncbi request reprint [Evaluation of systemic lupus erythematosus activity during pregnancy]
    Marzena Olesinska
    Klinika i Poliklinika Układowych Chorób Tkanki Lacznej, Instytut Reumatologii, Warszawa
    Pol Arch Med Wewn 117:312-6. 2007
    ..Point values are ascribed to individual parameters depending on their intensity...